BioSpace News Archive

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced that the company’s Chief Executive Officer, Mr. Amir Reichman, will attend the H.C. Wainwright 24th Annual Global Investment Conference in–person, and his pre–recorded presentation will be available during the conference via the online conference portal at https://hcwevents.com/annualconference.

Propanc Biopharma, Inc. announced significant effects of PRP against the tumor microenvironment and pre-metastatic niche has been reported by the Company’s joint researcher, Mrs. Belén Toledo Cutillas MSc, at the laboratory of Professor Macarena Perán, PhD, University of Jaén.

Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of a next-generation RhinAer® stylus.

P360, a leading technology developer for pharmaceutical companies, has unveiled that its BirdzAI data and analytics platform has been enhanced with four powerful new pre-built modules for Master Data Management, Insights & Analytics, Sales Operations and Marketing Operations.

Deka Biosciences announced the appointment of Charlotte Moser, MD, PhD, MSc, MBA as Chief Medical Officer and Deb Kientop, MBA as Vice President, Clinical Operations.

According to the current analysis of Reports and Data, the global artificial tendons and ligaments market was valued at USD 23.16 Billion in 2020 and is expected to reach USD 60.90 Billion by the year 2028, at a CAGR of 13.2%

Verana Health®—a digital health company elevating quality in real-world data—today announced it will present two research posters at the American College of Epidemiology (ACE) 2022 Annual Meeting.

The US Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to Attune Medical to evaluate the company’s ensoETM in the reduction of esophageal thermal injury during cardiac radiofrequency ablation procedures.

TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology.

The global clinical trial software market size reached USD 900.3 Million in 2020 and is expected to register a revenue CAGR of 15.6%, during the forecast period, according to latest analysis by Emergen Research.